Skip to Main Content

Paper Details

Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
Clin Pharmacol Ther
21
2020
AML, CYP2C19, CYP2C19*1, CYP2C19*1/*17, CYP2C19*17, CYP2C19*17/*, CYP2C19*2, *3, and *17 alleles, Neutropenic Acute Myeloid Leukemia, Patients, Voriconazole, fungal infections, neutropenic acute myeloid leukemia, patients, voriconazole
Author NameAffiliation
James K HicksH. Lee Moffitt Cancer Center and Research Institute
Brooke L FridleyH. Lee Moffitt Cancer Center and Research Institute
Howard L McLeodH. Lee Moffitt Cancer Center and Research Institute
Howard L McLeodH. Lee Moffitt Cancer Center and Research Institute
  • 1 - 4

Datasets

Release 1.2